文献速递白血病

嵌合抗原受体T细胞疗法治疗复发或难治性儿童B细胞急性淋巴细胞白血病的成本效益

Cost Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Relapsed or Refractory Pediatric B-Cell Acute Lymphoblastic Leukemia.
PubMed 文献 · J Clin Oncol · 2018-09-13

该研究采用Markov模型从美国医疗支付方视角评估替沙基仑赛治疗儿童复发或难治性急性淋巴细胞白血病的成本效益,并与博纳吐单抗、氯法拉滨联合方案及氯法拉滨单药比较。结果显示替沙基仑赛的成本效益高度依赖长期无复发生存率,5年无复发生存率40%时每增加1个质量调整生命年(QALY)需61,000美元,20%时为151,000美元,0%且作为移植桥接时为184,000美元。

要点

  • 5年无复发生存率40%时,替沙基仑赛每QALY成本为61,000美元。
  • 5年无复发生存率20%时,每QALY成本升至151,000美元。
  • 5年无复发生存率0%且作为移植桥接时,每QALY成本为184,000美元。

核心结论

  • 替沙基仑赛的长期有效性是其成本效益的关键但不确定的决定因素。
  • 在当前价格下,若能使相当比例患者无需移植而维持缓解,则具有合理价值;若所有患者最终需移植维持缓解,则在普遍接受的阈值下不具有成本效益。

研究设计与样本

  • 采用Markov模型,从美国医疗支付方视角,在终生时间范围内评估替沙基仑赛治疗儿童复发或难治性急性淋巴细胞白血病。
  • 模型基于近期多中心单臂临床试验数据,比较替沙基仑赛(在一系列合理的长期有效性假设下)与博纳吐单抗、氯法拉滨联合方案(氯法拉滨、依托泊苷和环磷酰胺)及氯法拉滨单药。
  • 使用情景分析和概率敏感性分析探索不确定性。

主要发现

  • 假设5年无复发生存率为40%时,替沙基仑赛增加12.1年预期寿命,每增加1个QALY的成本为61,000美元。
  • 5年无复发生存率为20%时,预期寿命增加3.8年,每增加1个QALY的成本为151,000美元。
  • 5年无复发生存率为0%且作为移植桥接时,预期寿命增加5.7年,每增加1个QALY的成本为184,000美元。
  • 将替沙基仑赛价格降至200,000美元或350,000美元,可使所有情景下均满足100,000美元/QALY或150,000美元/QALY的支付意愿阈值。

关键数值与推荐

  • 主要结局包括生命年、贴现终生成本、贴现质量调整生命年(QALY)和增量成本效益比(贴现率3%)。
  • 替沙基仑赛一次性输注成本为475,000美元。

局限性

  • 替沙基仑赛的长期有效性不确定,是其成本效益的关键但不确定的决定因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The anti-CD19 chimeric antigen receptor T-cell therapy tisagenlecleucel was recently approved to treat relapsed or refractory pediatric acute lymphoblastic leukemia. With a one-time infusion cost of $475,000, tisagenlecleucel is currently the most expensive oncologic therapy. We aimed to determine whether tisagenlecleucel is cost effective compared with currently available treatments. METHODS: Markov modeling was used to evaluate tisagenlecleucel in pediatric relapsed or refractory acute lymphoblastic leukemia from a US health payer perspective over a lifetime horizon. The model was informed by recent multicenter, single-arm clinical trials. Tisagenlecleucel (under a range of plausible long-term effectiveness) was compared with blinatumomab, clofarabine combination therapy (clofarabine, etoposide, and cyclophosphamide), and clofarabine monotherapy. Scenario and probabilistic sensitivity analyses were used to explore uncertainty. Main outcomes were life-years, discounted lifetime costs, discounted quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratio (3% discount rate). RESULTS: With an assumption of a 40% 5-year relapse-free survival rate, tisagenlecleucel increased life expectancies by 12.1 years and cost $61,000/QALY gained. However, at a 20% 5-year relapse-free survival rate, life-expectancies were more modest (3.8 years) and expensive ($151,000/QALY gained). At a 0% 5-year relapse-free survival rate and with use as a bridge to transplant, tisagenlecleucel increased life expectancies by 5.7 years and cost $184,000/QALY gained. Reduction of the price of tisagenlecleucel to $200,000 or $350,000 would allow it to meet a $100,000/QALY or $150,000/QALY willingness-to-pay threshold in all scenarios. CONCLUSION: The long-term effectiveness of tisagenlecleucel is a critical but uncertain determinant of its cost effectiveness. At its current price, tisagenlecleucel represents reasonable value if it can keep a substantial fraction of patients in remission without transplantation; however, if all patients ultimately require a transplantation to remain in remission, it will not be cost effective at generally accepted thresholds. Price reductions would favorably influence cost effectiveness even if long-term clinical outcomes are modest.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Lin JK, Lerman BJ, Barnes JI, et al. Cost Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Relapsed or Refractory Pediatric B-Cell Acute Lymphoblastic Leukemia. J Clin Oncol. 2018. PMID: 30212291. doi:10.1200/JCO.2018.79.0642

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。